Innoviva Inc (NASDAQ:INVA) — Market Cap & Net Worth
Market Cap & Net Worth: Innoviva Inc (INVA)
Innoviva Inc (NASDAQ:INVA) has a market capitalization of $1.57 Billion ($1.57 Billion) as of August 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6927 globally and #2141 in its home market, demonstrating a -1.08% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Innoviva Inc's stock price $20.97 by its total outstanding shares 74769062 (74.77 Million). See INVA capital reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
Innoviva Inc Market Cap History: 2015 to 2026
Innoviva Inc's market capitalization history from 2015 to 2026. Data shows growth from $788.07 Million to $1.57 Billion (8.32% CAGR).
Index Memberships
Innoviva Inc is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.06% | #197 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #782 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.72 Trillion | 0.09% | #123 of 263 |
|
S&P Small-Cap 600 Index
SML
|
$1.60 Trillion | 0.08% | #376 of 602 |
Weight: Innoviva Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Innoviva Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Innoviva Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.52x
Innoviva Inc's market cap is 3.52 times its annual revenue
Latest Price to Earnings (P/E) Ratio
5.51x
Innoviva Inc's market cap is 5.51 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $800.03 Million | $133.57 Million | $59.54 Million | 5.99x | 13.44x |
| 2017 | $1.06 Billion | $217.22 Million | $134.14 Million | 4.88x | 7.91x |
| 2018 | $1.30 Billion | $261.00 Million | $395.06 Million | 5.00x | 3.30x |
| 2019 | $1.06 Billion | $261.02 Million | $157.29 Million | 4.06x | 6.73x |
| 2020 | $926.39 Million | $336.79 Million | $224.40 Million | 2.75x | 4.13x |
| 2021 | $1.29 Billion | $391.87 Million | $265.85 Million | 3.29x | 4.85x |
| 2022 | $990.69 Million | $331.34 Million | $213.92 Million | 2.99x | 4.63x |
| 2023 | $1.20 Billion | $310.46 Million | $179.72 Million | 3.86x | 6.67x |
| 2024 | $1.30 Billion | $358.71 Million | $23.39 Million | 3.62x | 55.46x |
| 2025 | $1.49 Billion | $425.13 Million | $271.17 Million | 3.52x | 5.51x |
Competitor Companies of INVA by Market Capitalization
Companies near Innoviva Inc in the global market cap rankings as of August 2, 2026.
Key companies related to Innoviva Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Innoviva Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Innoviva Inc's market cap moved from $788.07 Million to $ 1.57 Billion, with a yearly change of 8.32%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.57 Billion | +4.90% |
| 2025 | $1.49 Billion | +15.22% |
| 2024 | $1.30 Billion | +8.17% |
| 2023 | $1.20 Billion | +21.06% |
| 2022 | $990.69 Million | -23.19% |
| 2021 | $1.29 Billion | +39.23% |
| 2020 | $926.39 Million | -12.50% |
| 2019 | $1.06 Billion | -18.85% |
| 2018 | $1.30 Billion | +22.97% |
| 2017 | $1.06 Billion | +32.62% |
| 2016 | $800.03 Million | +1.52% |
| 2015 | $788.07 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 2nd, 2026 the market cap of Innoviva Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.57 Billion USD |
| MoneyControl | $1.57 Billion USD |
| MarketWatch | $1.57 Billion USD |
| marketcap.company | $1.57 Billion USD |
| Reuters | $1.57 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Innoviva Inc
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The com… Read more